Immix Biopharma Director Carey Ng Receives Equity Awards

Immix Biopharma, Inc. director Carey Ng received equity compensation on May 22, 2026, including 6,250 restricted stock units (RSUs) that will vest on the earlier of the one-year anniversary or the company's 2027 annual meeting, and 12,500 stock options with an exercise price of $8.78 that vest monthly over 12 months. The RSUs were granted at $0 per share, bringing Ng's direct holdings to 26,250 common shares. Additionally, Ng has indirect beneficial ownership of 1,025,221 shares through Mesa Verde Venture Partners III, LP, where he serves as Managing Director. The filing represents standard director compensation through equity awards under the company's 2021 Equity Incentive Plan, with vesting tied to continued board service.